Hilltelligence markHilltelligence
Bills/H.R. 1082119th Congress

Shandra Eisenga Human Cell and Tissue Product Safety Act

Senate: Received
Cosponsors
1
Introduced
2025-02-06
Last action
2025-06-24

Received in the Senate and Read twice and referred to the Committee on Health, Education, Labor, and Pensions.

Sign in to view Hilltelligence’s plain-English summary.

Action Timeline
  1. SenateLatest

    Received in the Senate and Read twice and referred to the Committee on Health, Education, Labor, and Pensions.

  2. House

    Motion to reconsider laid on the table Agreed to without objection.

  3. House

    On motion to suspend the rules and pass the bill Agreed to by voice vote. (text: CR H2860-2861)

  4. House

    Passed/agreed to in House: On motion to suspend the rules and pass the bill Agreed to by voice vote. (text: CR H2860-2861)

  5. House

    DEBATE - The House proceeded with forty minutes of debate on H.R. 1082.

  6. House

    Considered under suspension of the rules. (consideration: CR H2860-2862)

  7. House

    Mr. Bilirakis moved to suspend the rules and pass the bill.

  8. House

    Placed on the Union Calendar, Calendar No. 127.

  9. House

    Reported by the Committee on Energy and Commerce. H. Rept. 119-160.

  10. House

    Ordered to be Reported by Voice Vote.

  11. House

    Committee Consideration and Mark-up Session Held

  12. House

    Referred to the House Committee on Energy and Commerce.

  13. House

    Introduced in House

Sign in to view Hilltelligence’s passage-probability analysis.

Official Sources
Topics

Policy area

Health

Legislative subjects

Administrative law and regulatory proceduresCivil actions and liabilityCongressional oversightDepartment of Health and Human ServicesHealth programs administration and fundingHealth promotion and preventive careOrgan and tissue donation and transplantation